Ibrutinib-A double-edge sword in cancer and autoimmune disorders

Journal of Drug Targeting

Volumn 24, Issue 5, 2016, Pages 373-385

  Kokhaei, Parviz ^a,b   Jadidi Niaragh, Farhad ^c   Sotoodeh Jahromi, Abdolreza ^d   Osterborg, Anders ^b,e   Mellstedt, Håkan ^b,e   Hojjat Farsangi, Mohammad ^b,f  

^a SEMNAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KAROLINSKA INSTITUTE   (Sweden)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d JAHROM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f BUSHEHR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bruton's tyrosine kinase; ibrutinib; Ror1; small molecule Inhibitors; targeted cancer therapy; tyrosine kinases

Indexed keywords

B LYMPHOCYTE RECEPTOR; BENDAMUSTINE; BRUTON TYROSINE KINASE; CARFILZOMIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE PHOSPHATE; IBRUTINIB; INDUCIBLE TYROSINE KINASE; INTERLEUKIN 2; LENALIDOMIDE; OFATUMUMAB; PALBOCICLIB; PREDNISONE; PROTEIN ROR1; PROTEIN TYROSINE KINASE; RITUXIMAB; TEMSIROLIMUS; UBLITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; IMMUNOLOGIC FACTOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; DRUG ACTIVITY; DRUG ADSORPTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME STRUCTURE; FOLLICULAR LYMPHOMA; HAIRY CELL LEUKEMIA; HUMAN; IMMUNOMODULATION; INFECTION; LARGE CELL LYMPHOMA; LEUKEMIA; LYMPHATIC LEUKEMIA; LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE MYELOMA; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROLYMPHOCYTIC LEUKEMIA; PROTEIN FUNCTION; REVIEW; SMALL LYMPHOCYTIC LEUKEMIA; T LYMPHOCYTE; TUMOR CELL; WALDENSTROEM MACROGLOBULINEMIA; ANIMAL; AUTOIMMUNE DISEASES; METABOLISM; NEOPLASMS;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; IMMUNOLOGIC FACTORS; NEOPLASMS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES;

EID: 84941254454     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2015.1086357     Document Type: Review

References (130)

1. Hojjat-Farsangi M. Novel and emerging targeted-based cancer therapy agents and methods. Tumour Biol 2015; 36: 543-56
2. Banham-Hall E, Clatworthy MR, Okkenhaug K. The therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases. Open Rheumatol J 2012; 6: 245-58
3. Hojjat-Farsangi M. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies. Int J Mol Sci 2014; 15: 13768-801
4. Kaliszczak M, Trousil S, Aberg O, et al. A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth. Br J Cancer 2013; 108: 342-50
5. Davidson D, Amrein L, Panasci L, Aloyz R. Small molecules, inhibitors of DNA-PK, targeting DNA repair, and beyond. Front Pharmacol 2013; 4: 1-7
6. Yao HP, Zhuang CM, Zhou YQ, et al. Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor. Curr Cancer Drug Targets 2013; 13: 686-97
7. Patterson H, Nibbs R, McInnes I, Siebert S. Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. Clin Exp Immunol 2014; 176: 1-10
8. Belmar J, Fesik SW. Small molecule Mcl-1 inhibitors for the treatment of cancer. Pharmacol Ther 2015; 145C: 76-84
9. Hojjat-Farsangi M. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances. J Drug Target 2015. [Epub ahead of print]. doi: 10.3109/1061186X.2015.1068319
10. Davids MS, Brown JR. Ibrutinib: a first in class covalent inhibitor of Brutons tyrosine kinase. Future Oncol 2014; 10: 957-67
11. Vargas L, Hamasy A, Nore BF, Smith CI. Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases. Scand J Immunol 2013; 78: 130-9
12. Hutcheson J, Vanarsa K, Bashmakov A, et al. Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus. Arthritis Res Ther 2012; 14: R243
13. Kil LP, de Bruijn MJ, van Nimwegen M, et al. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood 2012; 119: 3744-56
14. Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013; 122: 2539-49
15. Boukhiar MA, Roger C, Tran J, et al. Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma. Exp Hematol Oncol 2013; 2: 1-14
16. Darzentas N, Stamatopoulos K. Stereotyped B cell receptors in B cell leukemias and lymphomas. Methods Mol Biol 2013; 971: 135-48
17. Garcia-Munoz R, Llorente L. Chronic lymphocytic leukaemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms? Immunology 2014; 142: 536-50
18. Agathangelidis A, Vardi A, Baliakas P, Stamatopoulos K. Stereotyped B-cell receptors in chronic lymphocytic leukemia. Leuk Lymphoma 2014; 55: 2252-61
19. Palma M, Kokhaei P, Lundin J, et al. The biology and treatment of chronic lymphocytic leukemia. Ann Oncol 2006; 17: x144-54
20. Kokhaei P, Palma M, Mellstedt H, Choudhury A. Biology and treatment of chronic lymphocytic leukemia. Ann Oncol 2005; 16: ii113-23
21. Palma M, Adamson L, Hansson L, et al. Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia. Cancer Immunol Immunother 2008; 57: 1705-10
22. Zheng X, Ding N, Song Y, et al. Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment. Cancer Cell Int 2014; 14: 1-9
23. Niemann CU, Wiestner A. B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol 2013; 23: 410-21
24. Maura F, Cutrona G, Fabris S, et al. Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia. PLoS One 2011; 6: e24313
25. Forconi F, Potter KN, Sozzi E, et al. The IGHV1-69/IGHJ3 recombinations of unmutated CLL are distinct from those of normal B cells. Blood 2012; 119: 2106-9
26. de Weers M, Mensink RG, Kraakman ME, et al. Mutation analysis of the Brutons tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice. Hum Mol Genet 1994; 3: 161-6
27. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011; 117: 6287-96
28. Byrd JC, Brown JR, OBrien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213-23
29. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507-16
30. Xing L, Huang A. Brutons TK inhibitors: structural insights and evolution of clinical candidates. Future Med Chem 2014; 6: 675-95
31. Smith CI, Baskin B, Humire-Greiff P, et al. Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol 1994; 152: 557-65
32. Ellmeier W, Abramova A, Schebesta A. Tec family kinases: regulation of FcepsilonRI-mediated mast-cell activation. FEBS J 2011; 278: 1990-2000
33. Kawakami Y, Inagaki N, Salek-Ardakani S, et al. Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3. Proc Natl Acad Sci USA 2006; 103: 153-8
34. Schmidt U, Boucheron N, Unger B, Ellmeier W. The role of Tec family kinases in myeloid cells. Int Arch Allergy Immunol 2004; 134: 65-78
35. Maas A, Hendriks RW. Role of Brutons tyrosine kinase in B cell development. Dev Immunol 2001; 8: 171-81
36. Hartkamp LM, Fine JS, van Es IE, et al. Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants. Ann Rheum Dis 2015; 74: 1603-11
37. Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 2013; 34: 592-601
38. Baba Y, Hashimoto S, Matsushita M, et al. BLNK mediates Syk-dependent Btk activation. Proc Natl Acad Sci USA 2001; 98: 2582-6
39. Qiu Y, Kung HJ. Signaling network of the Btk family kinases. Oncogene 2000; 19: 5651-61
40. Vetrie D, Vorechovsky I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993; 361: 226-33
41. Lamba V, Ghosh I. New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors. Curr Pharm Des 2012; 18: 2936-45
42. Kufareva I, Abagyan R. Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. J Med Chem 2008; 51: 7921-32
43. Cox KJ, Shomin CD, Ghosh I. Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases. Future Med Chem 2011; 3: 29-43
44. Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007; 2: 58-61
45. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010; 107: 13075-80
46. Ni Gabhann J, Hams E, Smith S, et al. Btk regulates macrophage polarization in response to lipopolysaccharide. PLoS One 2014; 9: e85834
47. Bao Y, Zheng J, Han C, et al. Tyrosine kinase Btk is required for NK cell activation. J Biol Chem 2012; 287: 23769-78
48. Zorn CN, Keck S, Hendriks RW, et al. Brutons tyrosine kinase is dispensable for the Toll-like receptor-mediated activation of mast cells. Cell Signal 2009; 21: 79-86
49. Wang J, Lau KY, Jung J, tons tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells. Eur J Immunol 2014; 44: 1130-36
50. Lee SH, Kim T, Jeong D, et al. The tec family tyrosine kinase Btk regulates RANKL-induced osteoclast maturation. J Biol Chem 2008; 283: 11526-34
51. Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010; 116: 2078-88
52. Choi MY, Kipps TJ. Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J 2012; 18: 404-10
53. Sivina M, Kreitman RJ, Arons E, et al. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. Br J Haematol 2014; 166: 177-88
54. Jain N, O'Brien S. Ibrutinib (PCI-32765) in chronic lymphocytic leukemia. Hematol Oncol Clin North Am 2013; 27: 851-860
55. Winer ES, Ingham RR, Castillo JJ. PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs 2012; 21: 355-61
56. de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor-and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012; 119: 2590-4
57. Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012; 119: 1182-9
58. Herman SE, Mustafa RZ, Gyamfi JA, et al. Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood 2014; 123: 3286-95
59. Hojjat-Farsangi M, Jeddi-Tehrani M, Razavi SM, et al. Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia. Cancer Sci 2009; 100: 2346-53
60. Farsangi MH, Jeddi-Tehrani M, Sharifian RA, et al. Analysis of the immunoglobulin heavy chain variable region gene expression in Iranian patients with chronic lymphocytic leukemia. Leuk Lymphoma 2007; 48: 109-16
61. Lin K, Lane B, Carter A, et al. The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes on chromosome 17p. Br J Haematol 2013; 160: 53-62
62. Rushworth SA, Bowles KM, Barrera LN, et al. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB. Cell Signal 2013; 25: 106-112
63. Deng Y, Tao SD, Zhang X, et al. [Effect of PCI-32765 and bortezomib on proliferation and apoptosis of B-cell tumor cell lines and its mechanisms]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2013; 21: 1178-82
64. Grabinski N, Ewald F. Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells. Invest New Drugs 2014; 32: 1096-104
65. Ezell SA, Mayo M, Bihani T, et al. Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma. Oncotarget 2014; 5: 4990-5001
66. Mathews Griner LA, Guha R, Shinn P, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA 2014; 111: 2349-54
67. de Rooij MF, Kuil A, Kater AP, et al. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood 2015; 125: 2306-09
68. Advani R, Sharman J, Smith SM, et al. Effect of Btk Inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: evidence of antitumor activity from a phase I study. J Clin Oncol 2010; 28: 15s
69. Schwarzbich MA, Witzens-Harig M. Ibrutinib. Recent Results Cancer Res 2014; 201: 259-67
70. Chavez JC, Sahakian E, Pinilla-Ibarz J. Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evid 2013; 8: 37-45
71. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88-94
72. O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014; 15: 48-58
73. Brown JR, Barrientos JC, Barr PM, et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood 2015; 125: 2915-22
74. Younes A, Thieblemont C, Morschhauser F, et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol 2014; 15: 1019-26
75. Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2014; 15: 1090-9
76. Hallek M, Kay NE, Osterborg A, et al. The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future Oncol 2014; 11: 51-9
77. Siliciano JD, Morrow TA, Desiderio SV. itk, a T-cell-specific tyrosine kinase gene inducible by interleukin 2. Proc Natl Acad Sci USA 1992; 89: 11194-8
78. Iyer AS, Morales JL, Huang W, et al. Absence of Tec family kinases interleukin-2 inducible T cell kinase (Itk) and Brutons tyrosine kinase (Btk) severely impairs Fc epsilonRI-dependent mast cell responses. J Biol Chem 2011; 286: 9503-13
79. Prince AL, Yin CC, Enos ME, et al. The Tec kinases Itk and Rlk regulate conventional versus innate T-cell development. Immunol Rev 2009; 228: 115-31
80. Iyer AS, August A. The Tec family kinase, IL-2-inducible T cell kinase, differentially controls mast cell responses. J Immunol 2008; 180: 7869-77
81. Khurana D, Arneson LN, Schoon RA, et al. Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk. J Immunol 2007; 178: 3575-82
82. Dubois S, Waldmann TA, Muller JR. ITK and IL-15 support two distinct subsets of CD8+ T cells. Proc Natl Acad Sci USA 2006; 103: 12075-80
83. Gadue P, Stein PL. NK T cell precursors exhibit differential cytokine regulation and require Itk for efficient maturation. J Immunol 2002; 169: 2397-406
84. Andreotti AH, Schwartzberg PL, Joseph RE, Berg LJ. T-cell signaling regulated by the Tec family kinase, Itk. Cold Spring Harb Perspect Biol 2010; 2: a002287
85. Tsoukas CD, Grasis JA, Browne CD, Ching KA. Inducible T cell tyrosine kinase (ITK): structural requirements and actin polymerization. Adv Exp Med Biol 2006; 584: 29-41
86. Ching KA, Grasis JA, Tailor P, et al. TCR/CD3-Induced activation and binding of Emt/Itk to linker of activated T cell complexes: requirement for the Src homology 2 domain. J Immunol 2000; 165: 256-62
87. August A, Ragin MJ. Regulation of T-cell responses and disease by tec kinase Itk. Int Rev Immunol 2012; 31: 155-65
88. Pitcher LA, van Oers NS. T-cell receptor signal transmission: who gives an ITAM? Trends Immunol 2003; 24: 554-60
89. Rhee SG. Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem 2001; 70: 281-312
90. Liao XC, Littman DR. Altered T cell receptor signaling and disrupted T cell development in mice lacking Itk. Immunity 1995; 3: 757-69
91. Pastor RM, Burch JD, Magnuson S, et al. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors. Bioorg Med Chem Lett 2014; 24: 2448-52
92. Chang BY, Huang MM, Francesco M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther 2011; 13: R115
93. Burger JA, Buggy JJ. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma 2013; 54: 2385-91
94. Di Paolo JA, Huang T, Balazs M, et al. Specific Btk inhibition suppresses B cell-and myeloid cell-mediated arthritis. Nat Chem Biol 2011; 7: 41-50
95. Kubo T, Uchida Y, Watanabe Y, et al. Augmented TLR9-induced Btk activation in PIR-B-deficient B-1 cells provokes excessive autoantibody production and autoimmunity. J Exp Med 2009; 206: 1971-82
96. Chang BY, Thiemann P, Francesco M, et al. E. PCI-45292, a novel Btk Inhibitor with optimized pharmaceutical properties, demonstrates potent activities in mouse models of arthritis. Arthritis Rheum 2010; 62: 286
97. Shinohara M, Chang BY, Buggy JJ, et al. The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss. Bone 2014; 60: 8-15
98. Trible RP, Emert-Sedlak L, Smithgall TE. HIV-1 Nef selectively activates Src family kinases Hck, Lyn, and c-Src through direct SH3 domain interaction. J Biol Chem 2006; 281: 27029-38
99. Tarafdar S, Poe JA, Smithgall TE. The accessory factor nef links HIV-1 to Tec/Btk kinases in an Src homology 3 domain-dependent manner. J Biol Chem 2014; 289: 15718-8
100. Schiralli Lester GM, Akiyama H, et al. Interleukin 2-inducible T cell kinase (ITK) facilitates efficient egress of HIV-1 by coordinating Gag distribution and actin organization. Virology 2013; 436: 235-43
101. Fan K, Jia Y, Wang S, et al. Role of Itk signalling in the interaction between influenza A virus and T-cells. J Gen Virol 2012; 93: 987-97
102. Readinger JA, Schiralli GM, Jiang JK, et al. Selective targeting of ITK blocks multiple steps of HIV replication. Proc Natl Acad Sci USA 2008; 105: 6684-9
103. Alder CM, Ambler M, Campbell AJ, et al. Identification of a novel and selective series of Itk inhibitors via a template-hopping strategy. ACS Med Chem Lett 2013; 4: 948-52
104. Burch JD, Lau K, Barker JJ, et al. Property-and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitors. J Med Chem 2014; 57: 5714-27
105. Sahu N, Venegas AM, Jankovic D, et al. Selective expression rather than specific function of Txk and Itk regulate Th1 and Th2 responses. J Immunol 2008; 181: 6125-31
106. Benson M, Mobini R, Barrenas F, et al. A haplotype in the inducible T-cell tyrosine kinase is a risk factor for seasonal allergic rhinitis. Allergy 2009; 64: 1286-91
107. MacGlashan D, Jr, Honigberg LA, Smith A, et al. Inhibition of IgE-mediated secretion from human basophils with a highly selective Brutons tyrosine kinase, Btk, inhibitor. Int Immunopharmacol 2011; 11: 475-9
108. Ruderman EM, Pope RM. More than just B-cell inhibition. Arthritis Res Ther 2011; 13: 125
109. Vijayan V, Baumgart-Vogt E, Naidu S, et al. Brutons tyrosine kinase is required for TLR-dependent heme oxygenase-1 gene activation via Nrf2 in macrophages. J Immunol 2011; 187: 817-27
110. Huang Q, Pope RM. Toll-like receptor signaling: a potential link among rheumatoid arthritis, systemic lupus, and atherosclerosis. J Leukoc Biol 2010; 88: 253-62
111. Hojjat-Farsangi M, Khan AS, Daneshmanesh AH, et al. The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells. PLoS One 2013; 8: e78339
112. Hojjat-Farsangi M, Ghaemimanesh F, Daneshmanesh AH, et al. Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells. PLoS One 2013; 8: e61167
113. Shabani M, Asgarian Omran H, Farsangi MH, et al. Comparative expression profile of orphan receptor tyrosine kinase ROR1 in Iranian patients with lymphoid and myeloid leukemias. Avicenna J Med Biotechnol 2011; 3: 119-25
114. Hojjat-Farsangi M, Moshfegh A, Daneshmanesh AH, et al. The receptor tyrosine kinase ROR1-an oncofetal antigen for targeted cancer therapy. Semin Cancer Biol 2014; 29C: 21-31
115. Bicocca VT, Chang BH, Masouleh BK, et al. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell 2012; 22: 656-67
116. Shabani M, Naseri J, Shokri F. Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy. Expert Opin Ther Targets 2015; 19: 941-55
117. Byrd JC, OBrien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 1278-9
118. Kharfan-Dabaja MA, Wierda WG, Cooper LJ. Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia 2014; 28: 507-17
119. Liu J, Fitzgerald ME, Berndt MC, et al. Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood 2006; 108: 2596-603
120. Quek LS, Bolen J, Watson SP. A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol 1998; 8: 1137-40
121. Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia 2015; 29: 783-7
122. Conley ME, Dobbs AK, Farmer DM, et al. Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol 2009; 27: 199-227
123. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-92
124. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73
125. Awad MM, Katayama R, McTigue M, et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 2013; 368: 2395-401
126. Smith CC, Wang Q, Chin CS, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012; 485: 260-3
127. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11: 4182-90
128. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32-42
129. Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014; 370: 2286-94
130. Cheng S, Guo A, Lu P, et al. Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. Leukemia 2015; 29: 895-900